Introduction
Type IIB is a variant form of von Willebrand disease (vWD)1 characterized by responsiveness of platelet-rich plasma to con-centrations of ristocetin lower than those necessary to induce aggregation in normal (1, 2) . This finding is thought to be the consequence of enhanced interaction of the abnormal IIB von Willebrand factor (vWF) molecule with platelets (3), a situation different from that seen in pseudo-(4) or platelet-type vWD (5) in which abnormal platelet receptors show enhanced interaction with normal vWF (6) . More recently, purified IIB vWF has been shown to induce platelet aggregation in vitro without the need of any other agonist (7, 8) . Binding of IIB vWF, and particularly the larger multimers, to platelets in vivo provides a reasonable explanation for three findings typical of IIB vWD, namely: the lack of large vWF multimers in the plasma of these patients, but their presence in the cellular compartment (2, 9) ; the accelerated removal of large vWF multimers following their release into the circulation after infusion of l-desamino-8-D-arginine vasopressin (DDAVP) (3, 9) ; and the thrombocytopenia observed in these patients after administration of DDAVP (10) .
The molecular abnormality responsible for the direct binding ofIIB vWF to platelets is still undefined. Gralnick and co-workers have found that the sialic acid and galactose content was decreased in the vWF isolated from one IIB vWD patient (8) . This observation led them to suggest that IIB vWF might function in a manner similar to normal desialylated vWF (1 1-13) . Against this hypothesis is the finding that normal and IIB vWF have a similar isoelectric point that is lower than that of asialo vWF (14) .
We report here our findings in patients from three unrelated families with type IIB vWD. In one family, spontaneous platelet aggregation and thrombocytopenia were observed in the affected members. The sialic acid content of vWF purified from all these patients was normal. Nevertheless, IIB vWF bound to platelet membrane glycoprotein (GP)Ib in the absence of ristocetin and caused platelets to interact with each other. Optimal aggregation required endogenous ADP, a normally active platelet metabolism and exposure ofthe receptor for adhesive proteins on the GPIIb/ IIIa complex. Fibrinogen binding to this receptor resulted in maximal aggregation. In the absence of fibrinogen, however, vWF could partly substitute for its function. Moreover, these studies demonstrate that the binding ofIIB vWF to GPIb involves a molecular domain closely related to the one mediating the ristocetin-dependent binding of normal vWF.
Methods
All blood samples were obtained from patients and normal volunteers with their informed consent and in accordance with the Declaration of Helsinki. They had taken no medications for at least 2 wk. The afibrinogenemic patient (V.M.) has been described in a previous publication (15) .
Purifcation ofproteins. The purification of vWF was performed as reported (7, 11) . Starting material was citrated plasma obtained by plasmapheresis. Three different preparations ofIIB vWF were obtained from (a) 1,700 ml of plasma from one patient (D.Z.) previously described in detail (reference 1, patient 19, Table II ); (b) 2,000 ml ofplasma obtained from two patients from the same family (P.). These patients fulfilled the criteria for IIB vWD and, in addition, presented spontaneous platelet aggregation in platelet-rich plasma and had transient episodes ofthrombocytopenia. They have not been previously reported; and (c) 1,300 ml of pooled plasma from three patients belonging to another family (C.) previously described (reference 1, patients 12, 13, 16, Table II ). The isoelectric point of plasma vWF was measured in patients from two of these families (D.Z. and C.) and was similar to normal (14) . In addition, normal vWF was purified from 1 liter of plasma obtained either from single volunteers or pooled from four different donors. Purified vWF was contained in the first protein peak (detected by light absorbance at 280 nm) eluting at the void volume of the gel filtration column (7, 1 1).
The peak was smaller in the patients as compared with normal, because ofthe lower content of vWF, and its ascending part was less represented, because ofthe relative decrease of larger multimers, but no difference in elution position was detected. The final yields (based on recovery of ristocetin cofactor activity) were: 17-25% for normal; 3.2% for patient D.Z.; 5.2% for family P.; and 3.7% for family C. The lower yield of patient vWF is due to the lower efficiency of the cryoprecipitation step, due to the decreased concentration of larger multimers. Analysis of the purified vWF on reduced polyacrylnmide gels (16, 17) showed a major band with apparent mobility of 220 kD in both normal and patients and some smaller bands, due to proteolytic degradation, which were increased in the patients (16) . All the bands stained by Coomassie Blue were identified as vWF by immunoblotting (17) . Purified normal and IIB vWF were stored in 0.02 M Tris HCI, 0.15 M NaCl, pH 7.3 (Tris buffer), and kept at -70'C. Ristocetin cofactor activity and multimeric composition were tested as previously reported (7, (18) (19) (20) . 1 U of ristocetin cofactor activity corresponds to the amount present in 1 ml of pooled normal plasma.
Fibrinogen was purified and characterized as reported (21) . It was stored in 0.02 M Tris* HCI, 0.15 M NaCl, pH 7.3, at -70'C. Over 95% of the protein clotted when thrombin was added.
The reduced and alkylated 52/48 kD tryptic fragment of vWF was prepared and characterized as recently described (22) Desialylation of vWF. Normal purified vWF was treated with protease-free neuraminidase from Vibrio cholerae (Calbiochem-Behring Corp., La Jolla, CA) as previously described (11) . Over 90% of the sialic acid content of vWF was removed by this treatment.
Sialic acid measurement. The sialic acid content of vWF was measured according to the method of Warren (25) (2, 19) . The arrow at the top indicates the interface between stacking and running gel, the one at the bottom indicates the dye front. Cathode at the top. Note the lack of largest vWF multimers in the patient samples.
concentrations of patients vWF than used in the experiment described in Fig. 2 gave aggregation after a longer lag phase and to a lesser extent; higher concentrations gave more rapid aggregation. The aggregation, therefore, was dose dependent. It should be noted that the response of different individual platelet-rich plasmas to the same concentration of IIB vWF varied to a considerable extent, particularly when submaximal aggregating doses were used, as is true for any other platelet agonist.
Sialic acid content ofpurified IIB vWF. The content ofsialic acid was normal in the three IIB vWF preparations (Table I) (Fig. 4 ). An anti-GPIIb/IIIa monoclonal antibody (LJ-CP8) that blocks platelet binding of adhesive proteins (fibrinogen, vWF, and fibronectin) inhibited aggregation markedly, although an initial response ofplatelets was still visible when higher concentrations of IIB vWF were used (Fig. 4) . A similar response was observed when high concentrations of IIB vWF from the other two families were used. As discussed later, this platelet response may be mediated by vWF binding to GPIb and, therefore, may be considered agglutination rather than aggregation. In contrast, an anti-GPIIb/IIIa monoclonal antibody (IUJ-PS) that blocks only vWF, but not fibrinogen nor fibronectin binding, had no effect on I1B vWF-induced aggregation ofnormal platelet-rich plasma (Fig. 4) . Antibody UJ-P5, however, completely inhibited IIB vWF-induced aggregation in afibrinogenemic platelet-rich plasma, but its effect could be overcome by the addition of purified fibrinogen (Fig. 5) . It is also noteworthy that IIB vWF-induced aggregation in afibrinogenemic plateletrich plasma occurred after a longer lag phase, but proceeded to the same maximal extent as seen in the presence of fibrinogen (Fig. 5) . As with normal platelet-rich plasma, the extent of aggregation was dose dependent. The addition ofpurified IIB vWF to formalin-fixed platelets resulted in agglutination that was blocked by the anti-GPIb antibody, but minimally affected by the anti-GPIIb/IIIa antibody (LJ-CP8) that inhibited aggregation of metabolically active platelets (Fig. 6 ). As expected, the antibody LJ-P5 (which, like U-CP8, inhibits vWF binding to GPIIb/ HIIa) had no effect on the agglutination offormalin-fixed platelets.
The ADP scavenger, apyrase, could block completely platelet aggregation induced by low concentrations of IIB vWF isolated from the patients of family P. In noticeably affected by the presence of apyrase, but late disaggregation occurred when the ADP scavenger was present (Fig.  7) . Similar results were obtained with vWF from patient D.Z., whereas the aggregation induced by all tested concentrations (up to 15 ztg/ml) of vWF from family C was always blocked by apyrase. In the presence of indomethacin, a nonsteroidal antiinflammatory compound that acts as an antiaggregating agent by interfering with the platelet prostaglandin metabolism, the second wave of aggregation induced by high concentrations of IIB vWF (family P) was inhibited. Similar results, with an additional slight decrease of the initial platelet response, were observed when indomethacin and apyrase were used together (Fig. 7) .
Effect ofthe 52/48 kD trypticfragment ofvWF on IIB vWFinduced aggregation. A 52/48-kD tryptic fragment of normal vWF that contains the domain interacting with GPIb has recently been characterized (22) . This reduced and S-carboxymethylated fragment inhibits ristocetin-induced aggregation as well as asialo vWF-induced aggregation of normal platelet-rich plasma, and blocks the binding of normal vWF to GPIb in the presence of ristocetin. The 52/48-kD fragment of normal vWF completely inhibited aggregation induced by all three purified IIB vWF preparations (Fig. 8) Citrated platelet-rich plasma was prepared as described in Methods and incubated (final platelet count = 108/ml) with increasing concentrations of '251-asialo vWF (between 8 and 56 ;tg/ml), in the presence or absence of EDTA or apyrase at the indicated concentrations. After 30 min at 370C, without agitation, the platelets were separated from the binding mixture and the associated radioactivity was determined as described in Methods. The binding parameters were calculated using the computer assisted program Ligand (35) and assuming a molecular mass for vWF of 275 kD. Nonspecific binding was calculated as a fitted parameter and was found to be 0 for all curves.
family C. (Fig. 8 ). This is in agreement with the observat IIB vWF from family P. was a more potent aggregatir than the other two preparations. Effect ofdivalent cations and apyrase on asialo vWF to nonstimulated platelets. Desialylated vWF binds to I the absence of ristocetin and the binding can be demo] directly in platelet-rich plasma (1 1, 13) . In the present we found that removal of divalent cations with EDTA in increased binding as compared with that observed in platelet-rich plasma, without relevant changes in the diss constant of the interaction (Table II) . Under all circum the binding was inhibited > 90% in the presence of t GPIb monoclonal antibody LJ-Ibl. The (Fig. 9 ). When the Ca2" concentration was between 0.5-2 mM, the binding was only 30% ofthat observed in the presence of EDTA (Fig. 9 ). IIB vWF has a normal isoelectric point, whereas that ofdesialylated vWF is markedly higher than normal (14) , but it is in contrast with the 50% decrease of sialic acid and galactose reported in one patient by others (8) . Even considering the possibility of heterogeneity in this regard, it is clear that desialylation is not the general pathogenetic mechanism by which IIB vWF acquires the property ofdirectly aggregating platelets, as proposed by some authors. In fact, these studies demonstrate that fully sialylated vWF can bind to GPIb in the absence of any other modifying substance.
Recently, it has been suggested that platelet aggregation induced by asialo vWF cannot occur in the presence of physiological concentrations of calcium (38) . Nevertheless, we demonstrate in this report that platelet aggregation induced by IIB vWF occurs in platelet-rich plasma containing normal levels of divalent cations, in agreement with the indirect evidence suggesting that the IIB vWF-platelet interaction can occur in vivo (10 Va,4I9 to Lys728 of the constituent subunit (22) . It is of interest that this 52/48-kD fragment isolated from normal vWF binds to platelets in the absence ofristocetin, thus suggesting that other regions of the molecule, or specific conformations lost in the isolated fragment, are responsible for modulating the binding of whole vWF to GPIb. It is also relevant that the carbohydrate contained in the 52/48 kD fragment does not play a role in its binding to GPIb nor prevents it (22) . These observations should help direct the efforts aimed at defining the molecular abnormality of type IIB vWF.
We and others have previously demonstrated that platelet aggregation induced by IIB vWF proceeds through exposure of the GPIIb/IIIa common receptor for adhesive proteins (7, 8) . Our initial interpretation was that fibrinogen binding to this receptor was necessary for aggregation to occur. The present studies, however, clearly demonstrate that vWF binding to GPIIb/IIIa can substitute for fibrinogen binding in mediating platelet aggreation induced by IIB vWF. This can only be shown in the absence offibrinogen and, in this regard, the findings with IIB vWF are similar to those obtained with other platelet agonists (29) .
Whereas maximal platelet aggregation in response to IIB vWF occurs only through the function of the GPIIb/IIIa common receptor for adhesive proteins, we found that platelet aggregation induced by higher concentrations of IIB vWF is not completely blocked by an anti-GPIIb/IIIa monoclonal antibody that totally inhibits the binding of fibrinogen and other adhesive molecules. Thus, the direct binding of IIB vWF to GPIb, in the absence of ristocetin, mediates platelet-platelet interaction even when the GPIIb/IIIa receptor is blocked. This was confirmed by the demonstration that IIB vWF agglutinates formalin-fixed platelets, and that such agglutination is blocked by the antiGPIb but not the anti-GPIIb/IlIa antibody. GPIb-mediated platelet agglutination, independent ofGPIIb/IIIa receptor function, was particularly evident with IIB vWF isolated from the family exhibiting spontaneous platelet aggregation in vitro and episodes of thrombocytopenia. This abnormal molecule may have higher affinity for GPIb than other IIB vWF molecules and seems to mimic more closely some of the ristocetin-dependent functions ofnormal vWF, like platelet agglutination independent of GPIIb/IIIa binding activity. In this regard, the disaggregation observed following the initial aggtion of metabolically active platelets in the presence of the anti-GPIIb/IIIa antibody may resemble the disaggregation of thrombasthenic platelets after ristocetin-induced aggregation (42) .
In conclusion, the present studies demonstrate that the GPIb binding domain ofIIB vWF is closely related to the one in normal vWF. Binding offully sialylated UB vWF to GPIb in the absence of ristocetin results in initial platelet-platelet interaction that is followed, with normal platelets, by exposure of the GPIIb/IIIa common receptor for adhesive proteins, a process dependent on endogenous ADP and active platelet metabolism. As with other agonists, fibrinogen binds preferentially to the exposed sites, but in the absence of fibrinogen vWF can bind to GPIIb/IIIa and mediate platelet aggregation.
